Product Description: Lipofermata is a fatty acid transport protein 2 (FATP2) inhibitor. Lipofermata shows fatty acid transport inhibition with an IC50 of 4.84 μM in Caco-2 cells. Lipofermata, an analog of spiro-indoline-thadiazole, shows zinc-specific suppression of antibacterial activity. Lipofermata perturbs zinc homeostasis in E. coli K-12 with a MIC of 16 μM[1][2][3].
Applications: Cancer-programmed cell death
Formula: C15H10BrN3OS
References: [1]Falconer SB, et al. Zinc Chelation by a Small-Molecule Adjuvant Potentiates Meropenem Activity in Vivo against NDM-1-Producing Klebsiella pneumoniae. ACS Infect Dis. 2015;1(11):533-543./[2]Sandoval A, et al. Identification and characterization of small compound inhibitors of human FATP2 [published correction appears in Biochem Pharmacol. 2012 Aug 15;84(4):580]. Biochem Pharmacol. 2010;79(7):990-999. /[3]Ahowesso C, Black PN, Saini N, et al. Chemical inhibition of fatty acid absorption and cellular uptake limits lipotoxic cell death. Biochem Pharmacol. 2015;98(1):167-181.
CAS Number: 297180-15-5
Molecular Weight: 360.23
Compound Purity: 99.75
Research Area: Infection
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: Bacterial
English
Deutsch
